Cargando…

MYCN acts as a direct co-regulator of p53 in MYCN amplified neuroblastoma

The MYC oncogenes and p53 have opposing yet interrelated roles in normal development and tumorigenesis. How MYCN expression alters the biology and clinical responsiveness of pediatric neuroblastoma remains poorly defined. Neuroblastoma is p53 wild type at diagnosis and repression of p53 signaling is...

Descripción completa

Detalles Bibliográficos
Autores principales:	Agarwal, Saurabh, Milazzo, Giorgio, Rajapakshe, Kimal, Bernardi, Ronald, Chen, Zaowen, Barberi, Eveline, Koster, Jan, Perini, Giovanni, Coarfa, Cristian, Shohet, Jason M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2018
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5945521/ https://www.ncbi.nlm.nih.gov/pubmed/29755654 http://dx.doi.org/10.18632/oncotarget.24859

Ejemplares similares

Correction: MYCN acts as a direct co-regulator of p53 in MYCN amplified neuroblastoma
por: Agarwal, Saurabh, et al.
Publicado: (2018)

MYCN is amplified during S phase, and c-myb is involved in controlling MYCN expression and amplification in MYCN-amplified neuroblastoma cell lines
por: Aygun, Nevim, et al.
Publicado: (2019)

MYCN upregulates the transsulfuration pathway to suppress the ferroptotic vulnerability in MYCN-amplified neuroblastoma
por: Floros, Konstantinos V., et al.
Publicado: (2022)

A MYCN-independent mechanism mediating secretome reprogramming and metastasis in MYCN-amplified neuroblastoma
por: Zhang, Hai-Feng, et al.
Publicado: (2023)

The MicroRNA Landscape of MYCN-Amplified Neuroblastoma
por: Misiak, Danny, et al.
Publicado: (2021)

MYCN-driven fatty acid uptake is a metabolic vulnerability in neuroblastoma
por: Tao, Ling, et al.
Publicado: (2022)

Elimination of MYCN-Amplified Neuroblastoma Cells by Telomerase-Targeted Oncolytic Virus via MYCN Suppression
por: Tanimoto, Terutaka, et al.
Publicado: (2020)

Molecular mechanisms of MYCN-dependent apoptosis and the MDM2–p53 pathway: an Achille’s heel to be exploited for the therapy of MYCN-amplified neuroblastoma
por: Petroni, Marialaura, et al.
Publicado: (2012)

FOXR2 Stabilizes MYCN Protein and Identifies Non–MYCN-Amplified Neuroblastoma Patients With Unfavorable Outcome
por: Schmitt-Hoffner, Felix, et al.
Publicado: (2021)

SMAD9-MYCN positive feedback loop represents a unique dependency for MYCN-amplified neuroblastoma
por: Tan, Kezhe, et al.
Publicado: (2022)

MYCN mRNA degradation and cancer suppression by a selective small-molecule inhibitor in MYCN-amplified neuroblastoma
por: Liu, Tao, et al.
Publicado: (2022)

Targeting condensin, a vital spot of MYCN-amplified neuroblastoma
por: Tanno, Yuji, et al.
Publicado: (2014)

Multi-omic profiling of MYCN-amplified neuroblastoma cell-lines
por: Dassi, Erik, et al.
Publicado: (2015)

Inhibitors of ribosome biogenesis repress the growth of MYCN-amplified neuroblastoma
por: Hald, Øyvind H., et al.
Publicado: (2018)

CAMKV Is a Candidate Immunotherapeutic Target in MYCN Amplified Neuroblastoma
por: Sussman, Robyn T., et al.
Publicado: (2020)

SGO1 is involved in the DNA damage response in MYCN-amplified neuroblastoma cells
por: Murakami-Tonami, Yuko, et al.
Publicado: (2016)

Genomic profile of MYCN non-amplified neuroblastoma and potential for immunotherapeutic strategies in neuroblastoma
por: Lee, Eunjin, et al.
Publicado: (2020)

MYCN-amplified neuroblastoma cell-derived exosomal miR-17-5p promotes proliferation and migration of non-MYCN amplified cells
por: Chen, Weiming, et al.
Publicado: (2021)

The synergy of BET inhibitors with aurora A kinase inhibitors in MYCN-amplified neuroblastoma is heightened with functional TP53
por: Yi, Joanna S., et al.
Publicado: (2021)

MYCN Function in Neuroblastoma Development
por: Otte, Jörg, et al.
Publicado: (2021)

MYCN and Metabolic Reprogramming in Neuroblastoma
por: Bansal, Mohit, et al.
Publicado: (2022)

Metastasis in neuroblastoma: the MYCN question
por: Bhavsar, Swapnil Parashram
Publicado: (2023)

The genetic tumor background is an important determinant for heterogeneous MYCN‐amplified neuroblastoma
por: Bogen, Dominik, et al.
Publicado: (2016)

Gene expression and molecular pathway activation signatures of MYCN-amplified neuroblastomas
por: Petrov, Ivan, et al.
Publicado: (2017)

Serine–glycine-one-carbon metabolism: vulnerabilities in MYCN-amplified neuroblastoma
por: Zhao, Erhu, et al.
Publicado: (2020)

EP300 Selectively Controls the Enhancer Landscape of MYCN-Amplified Neuroblastoma
por: Durbin, Adam D., et al.
Publicado: (2022)

Macrophage infiltration promotes regrowth in MYCN-amplified neuroblastoma after chemotherapy
por: Valind, Anders, et al.
Publicado: (2023)

The super elongation complex drives transcriptional addiction in MYCN-amplified neuroblastoma
por: Wang, Donghai, et al.
Publicado: (2023)

Exploitation of chick embryo environments to reprogram MYCN-amplified neuroblastoma cells to a benign phenotype, lacking detectable MYCN expression
por: Carter, R, et al.
Publicado: (2012)

Implementation of the plasma MYCN/NAGK ratio to detect MYCN amplification in patients with neuroblastoma
por: Su, Yan, et al.
Publicado: (2020)

Conditional expression of retrovirally delivered anti-MYCN shRNA as an in vitro model system to study neuronal differentiation in MYCN-amplified neuroblastoma
por: Henriksen, Jørn R, et al.
Publicado: (2011)

The long non-coding RNA MYCNOS-01 regulates MYCN protein levels and affects growth of MYCN-amplified rhabdomyosarcoma and neuroblastoma cells
por: O’Brien, Eleanor M., et al.
Publicado: (2018)

The MYCN inhibitor BGA002 restores the retinoic acid response leading to differentiation or apoptosis by the mTOR block in MYCN-amplified neuroblastoma
por: Lampis, Silvia, et al.
Publicado: (2022)

Single-Cell Gene Network Analysis and Transcriptional Landscape of MYCN-Amplified Neuroblastoma Cell Lines
por: Mercatelli, Daniele, et al.
Publicado: (2021)

Genetic variation associated with childhood and adult stature and risk of MYCN‐amplified neuroblastoma
por: Semmes, Eleanor C., et al.
Publicado: (2020)

Therapeutic targeting of both dihydroorotate dehydrogenase and nucleoside transport in MYCN-amplified neuroblastoma
por: Yu, Yajie, et al.
Publicado: (2021)

Therapeutic potential of targeting MYCN: A case series report of neuroblastoma with MYCN amplification
por: Huang, Can, et al.
Publicado: (2020)

Ferroptosis vulnerability in MYCN‐driven neuroblastomas
por: Dasgupta, Shayani, et al.
Publicado: (2022)

MYCN Amplifications and Metabolic Rewiring in Neuroblastoma
por: Pouliou, Marialena, et al.
Publicado: (2023)

Tumour-suppressor microRNAs let-7 and mir-101 target the proto-oncogene MYCN and inhibit cell proliferation in MYCN-amplified neuroblastoma
por: Buechner, J, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_88e2dsu5f0s34te4fkr19u5vh4